CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
Soy Isoflavones +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02007200
NCT02007200Phase 2Completed

A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma

National Cancer Institute (NCI)·interventional·Posted Dec 10, 2013·Updated Oct 24, 2016

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Soy Isoflavones, and 1 other intervention for Recurrent Hypopharyngeal Squamous Cell Carcinoma and 30 related conditions. Completed, enrolled 55 participants across 3 sites.

Detailed Summary

This phase II clinical trial studies how well soy isoflavones work in preventing head and neck cancer in patients with stage I-IV head and neck cancer undergoing surgery. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones may prevent head and neck cancer recurrence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 10, 2013
Enrollment StartJul 1, 2009
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 12.6 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Soy Isoflavonesdrug

Given PO

Survey Administrationother

Ancillary studies